bluebird bio Announces September Investor Events

Rhea-AI Summary

bluebird bio, Inc. (NASDAQ: BLUE) announced its participation in upcoming investor conferences, including the Wells Fargo Healthcare Conference on September 8, 2022, and the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022. The presentations can be accessed via the Investors & Media section of their website. bluebird bio focuses on curative gene therapies for severe genetic diseases, maintaining a deep commitment to patient communities.

Positive

• bluebird bio has a dedicated focus on severe genetic diseases, enhancing its business profile.
• Participation in major investor conferences can increase visibility and attract potential investors.

Negative

• None.

SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences:

• 2022 Wells Fargo Healthcare Conference, Thursday, September 8, at 9:10 a.m. ET at the Encore Boston Harbor, Everett, MA
• Morgan Stanley 20^th Annual Global Healthcare Conference, Tuesday, September 13, at 8:35 a.m. ET at the Sheraton New York, New York, NY

To access the live webcast of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcasts will be available on the bluebird bio website for 90 days following the event.

About bluebird bio, Inc.

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading clinical and research programs for sickle cell disease, beta-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. ​

For more information, visit bluebirdbio.com or follow us on social media at @bluebirdbio, LinkedIn, Instagram and YouTube.

bluebird bio is a trademark of bluebird bio, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005358/en/

Investors & Media

Investors:

Courtney O’Leary, 978-621-7347

coleary@bluebirdbio.com

Media:

Sarah Alspach, 857-299-6198

sarah.alspach@bluebirdbio.com

Source: bluebird bio, Inc.

FAQ

What conferences will bluebird bio participate in during September 2022?

bluebird bio will participate in the Wells Fargo Healthcare Conference on September 8, 2022, and the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022.

Where can I find the live webcast of bluebird bio's presentations?

The live webcast of bluebird bio's presentations can be accessed on their Investors & Media webpage.

What is the focus of bluebird bio's research and development?

bluebird bio focuses on curative gene therapies for severe genetic diseases, specifically targeting sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.